Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
03
11
2019
accepted:
26
01
2020
revised:
06
01
2020
pubmed:
6
2
2020
medline:
24
6
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Despite their theoretical rationale, nicotinic alpha-7 acetylcholine (nα
Identifiants
pubmed: 32015461
doi: 10.1038/s41386-020-0628-9
pii: 10.1038/s41386-020-0628-9
pmc: PMC7298033
doi:
Substances chimiques
Antipsychotic Agents
0
alpha7 Nicotinic Acetylcholine Receptor
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1339-1345Subventions
Organisme : NIMH NIH HHS
ID : U01 MH094247
Pays : United States
Références
Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs 2017;31:373–88.
pubmed: 28397113
Kurtz MM, Moberg JP, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005;31:167–74.
pubmed: 15888434
Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165–71.
pubmed: 11177118
Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, et al. Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in schizophrenia. Schizophr Bull 2016;42:19–33.
pubmed: 26362273
Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry. 2012;69:1216–24.
pubmed: 23026889
pmcid: 3976993
Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. 2015;16:620–31.
pubmed: 26373471
Gold R, Butler PD, Revheim N, Leitman DI, Hansen JA, Gur RC, et al. Auditory emotion recognition impairments in Schizophrenia: Relationship to acoustic features and cognition. Am J Psychiatry. 2012;169:424–32.
pubmed: 22362394
Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, et al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiatry. 2017;74:37–46.
pubmed: 27926742
pmcid: 5453308
Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873–83.
pubmed: 11743942
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl J Med. 2005;353:1209–23.
pubmed: 16172203
Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. 2018;108:57–83.
pubmed: 30055853
Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993–7.
pubmed: 3487983
Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1–5.
pubmed: 9193735
Lewis AS, van Schalkwyk GI, Bloch MH. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: a translational meta-analysis of rodent and human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75:45–53.
pubmed: 28065843
pmcid: 5446073
Freedman R. alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med. 2014;65:245–61.
pubmed: 24111888
Kantrowitz JT. N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia. Schizophr Res 2019;207:70–9.
pubmed: 29459050
Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC. Normalizing effects of EVP-6124, an Alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014;20:12–24.
pubmed: 24419307
Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, et al. The novel alpha7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology. 2014;231:4541–51.
pubmed: 24810107
Maex R, Grinevich VP, Grinevich V, Budygin E, Bencherif M, Gutkin B. Understanding the role alpha7 nicotinic receptors play in dopamine efflux in nucleus accumbens. ACS Chem Neurosci. 2014;5:1032–40.
pubmed: 25147933
pmcid: 4198061
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63:630–8.
pubmed: 16754836
Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, et al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013;64:197–204.
pubmed: 22766391
Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015;40:3053–60.
pubmed: 26089183
pmcid: 4864641
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an Alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013;38:968–75.
pubmed: 23303043
pmcid: 3629385
Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA. A Randomized trial to assess the efficacy and safety of ABT-126, a selective alpha7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia. Am J Psychiatry. 2016;173:appiajp201515010093.
Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, et al. A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2014;39:1568–77.
pubmed: 24549101
pmcid: 4023143
Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, et al. Pharmacokinetic limitations on effects of an Alpha7-nicotinic receptor agonist in schizophrenia: randomized trial with an extended-release formulation. Neuropsychopharmacology 2018;43:583–9.
pubmed: 28825423
Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, et al. Phase 2 trial of an Alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull 2016;42:335–43.
pubmed: 26071208
Haig GM, Wang D, Zhao J, Othman AA, Bain EE. Efficacy and Safety of the alpha7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers. J Clin Psychiatry. 2018;79. https://doi.org/10.4088/JCP.16m11162 .
Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci USA. 2007;104:8059–64.
pubmed: 17470817
Gee KW, Olincy A, Kanner R, Johnson L, Hogenkamp D, Harris J, et al. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. J Psychopharmacol 2017;31:434–41.
pubmed: 28196430
Grabb MC, Cross AJ, Potter WZ, McCracken JT. Derisking psychiatric drug development: the NIMH’s fast fail program, a novel precompetitive model. J Clin Psychopharmacol. 2016;36:419–21.
pubmed: 27404513
pmcid: 5007185
Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018;18:82–4.
pubmed: 30591715
pmcid: 6816017
Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018;75:11–9.
Kantrowitz JT, Swerdlow NR, Dunn W, Vinogradov S. Auditory system target engagement during plasticity-based interventions in schizophrenia: a focus on modulation of N-methyl-D-aspartate-type glutamate receptor function. Biol Psychiatry. 2018;3:581–90.
Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310–9.
Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983;18:537–51.
pubmed: 6134559
Overall JE, Gorham DE. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: The University of Iowa; 1984.
Ragland JD, Blumenfeld RS, Ramsay IS, Yonelinas A, Yoon J, Solomon M, et al. Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia. Neuroimage 2012;59:1719–26.
pubmed: 21907293
Ragland JD, Ranganath C, Barch DM, Gold JM, Haley B, MacDonald AW 3rd, et al. Relational and item-specific encoding (RISE): task development and psychometric characteristics. Schizophr Bull. 2012;38:114–24.
pubmed: 22124089
Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry. 1994;2:179–92.
pubmed: 9384901
Javitt DC, Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry. 2015;172:17–31.
pubmed: 25553496
Leonard S, Freedman R. Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry 2006;60:115–22.
pubmed: 16843094
Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E, et al. Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and item-specific encoding task. JAMA Psychiatry. 2015;72:909–16.
pubmed: 26200928
pmcid: 4558363
Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944–50.
pubmed: 10588409
Lee M, Sehatpour P, Dias EC, Silipo GS, Kantrowitz JT, Martinez AM, et al. A tale of two sites: differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. Schizophr Res 2018;191:10–7.
pubmed: 28779851
Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 2006;32:692–700.
pubmed: 16469942
pmcid: 2632276
Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004;161:1822–8.
pubmed: 15465979
Greenwood LM, Leung S, Michie PT, Green A, Nathan PJ, Fitzgerald P, et al. The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophr Res 2018;191:61–9.
pubmed: 28602646
Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, et al. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain 2016;139:3281–95.
pubmed: 27913408
pmcid: 5840885
Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res 2018;191:70–9.
pubmed: 28318835
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187–99.
pubmed: 18004285